KALARIS THERAPEUTICS, INC. Deferred Revenue Recognized
KALARIS THERAPEUTICS, INC. (KLRS) reported Deferred Revenue Recognized of $200.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-12.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2021-02-12
- KALARIS THERAPEUTICS, INC. contract with customer, liability, revenue recognized for fiscal 2019 was $200.00K.
| Period end | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|
| 2019-12-31 | $200.00K 10-K · filed 2021-02-12 | ||
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $200.00K 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |